Key result
Fenofibrate leads fibrates in lipid-lowering efficacy, cutting non-HDL-C by ~/dL versus placebo.
Why the study?
Do fibrates improve lipid profiles compared to placebo?
Meta-Analysis
Do fibrates improve lipid profiles compared to placebo?
Answers are grounded in this paper and cite their sources.
Fenofibrate demonstrates the most consistent and comprehensive lipid-lowering profile among fibrates, significantly reducing ApoB and non-HDL-C even when combined with statins.
We conducted a meta-analysis to compare the lipid-lowering effects of fibratesLiterature was searched up to December 2024. Absolute changes in triglycerides (TG), LDL-cholesterol (LDL‑C), apolipoprotein B (ApoB), and non-HDL cholesterol (non-HDL-C) were analyzed using both fixed and random effects models. We included 63 randomized controlled trials. Compared to placebo, all fibrates significantly reduced TG levels. Fenofibrate and bezafibrate significantly reduced LDL-C (–15.12 and –15.04 mg/dL, respectively), while only fenofibrate significantly lowered ApoB (–24.88 mg/dL) and non-HDL-C (–46.38 mg/dL), followed by gemfibrozil and pemafibrate for non-HDL-C. In combination with statins, no fibrates significantly reduced LDL-C, while fenofibrate remained the only fibrate to significantly lower ApoB (–10.42 mg/dL) and non-HDL-C (–12.02 mg/dL). Overall, we found that fibrates differ substantially in their lipid effects. Fenofibrate shows the most consistent and comprehensive lipid-lowering profile.
No takes yet. Share an insight, caveat, or question.
Olmastroni et al. (2025) conducted a meta-analysis in Dyslipidemia. Fibrates vs. Placebo or statins was evaluated on Absolute changes in triglycerides (TG), LDL-cholesterol (LDL-C), apolipoprotein B (ApoB), and non-HDL cholesterol (non-HDL-C). Fenofibrate showed the most consistent lipid-lowering profile among fibrates, reducing LDL-C, ApoB, and non-HDL-C compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: